Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shareholders might understandably be very concerned that the share price has dropped 34% in the last quarter. But that doesn't undermine the fantastic ...

Capricor Therapeutics (CAPR) closed the last trading session at $13.47, gaining 7.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it completed the submission of its Biologics License ...

Check the time stamp on this data. Updated AI-Generated Signals for Capricor Therapeutics Inc. (CAPR) available here: CAPR.

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating ...

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

Capricor Therapeutics (CAPR) announced the completion of the submission of its Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, seeking full approval for ...

Ratings for Capricor Therapeutics CAPR were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...